Central European Journal of Medicine

, Volume 2, Issue 2, pp 154–158 | Cite as

Integrin CD11a/CD18, CD11b/CD18 and CD69 expression in patients after renal transplantation

  • Jacek Rysz
  • Eugeniusz Kocur
  • Robert Błaszczak
  • Robert Stolarek
Research Article


Chronic renal failure (CRF) is a complex clinical entity caused by progressive destruction of functional renal parenchyma in the course of various pathological processes resulting in complete failure of renal function and subsequent metabolic, acid base and electrolyte as well as immune disorders. Renal transplantation (RT) is one of the renal replacement therapy options in the terminal stage of chronic renal failure. The replacement of the failing organ with one from a healthy donor may be complicated with immune host response. This study was designed to investigate the changes in serum concentration of integrins CD11a/CD18, CD11b/CD18, CD69 on the surface of human polymorphonuclear leukocytes (PMNL) after the RT within two six-month periods. The study included 25 RT patients (mean 5.4±2.7 yrs after the transplantation, 10 females and 15 males) treated with immune suppressive therapy including cyclosporine A, azathioprine and prednisolone. The expression was assessed with monoclonal antibodies by means of flow cytometry. Also, the expression of CD69 was determined before and after phytohemaglutinine (PHA) stimulation. There was no significant alternation in serum concentration of CD11a/CD18, CD11b/CD18 and CD69 at baseline, six months and twelve months later. The expression of integrins was not altered in renal transplantation patients in the current study setting.


Integrins renal transplantation chronic renal failure 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    A. Książek and B. Rutkowski: Nefrologia, Wydawnictwo Czelej, Lublin, 2004.Google Scholar
  2. [2]
    B. Descamps-Latscha., A. Herbelin, A.T. Nguyen, P. Roux-Lombard, J. Zingraff, A. Moynot, C. Verger, D. Dohmane, D. de Groote, P. Jungers and J.M. Dayer: “Balance between Il-1β, TNF-α and their specific inhibitors in chronic renal failure and maintenance dialysis”, J. Immunol., Vol. 154, (1995), pp. 882–892.PubMedGoogle Scholar
  3. [3]
    M. Jakóbisiak: Immunologia, Wydawnictwo Naukowe PWN, Warszawa, 1993.Google Scholar
  4. [4]
    I. Żak: “Receptory adhezyjne”, Adv. Cell Biol., Vol. 23, (1996), pp. 221–242.Google Scholar
  5. [5]
    A. Magi, S. Sumitran-Karuppan, A. Peetsalu and R. Uibo: “Early expression of CD69 in allogenic T cell activation”, Cent. Eur. J. Immunol., Vol. 22, (1997), pp. 86–93.Google Scholar
  6. [6]
    M.L. Allegre: “Costimulatory molecules as targets for the induction of transplantation tolerance”, Nephrol. Dial. Transplant., Vol. 14, (1999), pp. 322–332.CrossRefGoogle Scholar
  7. [7]
    A. Vink, P. Uyettenhove, P. Waunders and J. Van Snick: “Accessory factors involved in murine T cell activation. Distinct roles of interleukin 6, interleukin 1 and tumor necrosis factor”, Eur. J. Immunol., Vol. 20, (1990), pp. 1–6.PubMedCrossRefGoogle Scholar
  8. [8]
    A. J. McLaren, S.E. Marshall, N.K. Haldar, C.G. Mullighan, S.V. Fuggle, P.J. Morris and K.I. Welsh: “Adhesion molecule polymorphisms in chronic renal allograft failure”, Kidney Int., Vol. 55, (1999), pp. 1977–1982.PubMedCrossRefGoogle Scholar
  9. [9]
    E. Kocur, J. Karpinski, L. Pokoca, P. Wolkanin, B. Rogulski, K. Zeman, P. Kaczmarek and F. Kacprzyk: “Leukocyte differentiation antigens on peripheral blood cells in kidney allograft recipients”, 14th European Immunology Meeting, Poznań, 2000, pp. 785–788.Google Scholar
  10. [10]
    J. Malyszko, J.S. Malyszko, S. Brzosko, S. Wolczyński and M. Mysliwiec: “Markers of endothelial cell activation/injury: CD145 and thrombomodulin are related to adiponectin in kidney allograft recipients”, Am. J. Nephrol., Vol. 25, (2005), pp. 203–210.PubMedCrossRefGoogle Scholar
  11. [11]
    J. Rysz, M. Banach, R.A. Stolarek, J. Pasnik, A. Cialkowska-Rysz, L. Markuszewski and Z. Baj: “TNF-alpha priming effect on polymorphonuclear leukocyte reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients”, Arch. Immunol. Ther. Exp., Vol. 54, (2006), pp. 209–215.CrossRefGoogle Scholar
  12. [12]
    C. Schwarz, and R. Oberbauer: “The influence of organ donor factors on early allograft function”, Curr. Opin. Urol., Vol. 13, (2003), pp. 99–104.PubMedCrossRefGoogle Scholar
  13. [13]
    J. Rysz, P. Bartnicki and R.A. Stolarek: “Erythropoietin therapy in chronic renal failure patients prior to hemodialysis”, Arch. Med. Sci., Vol. 1, (2005), pp. 55–58.Google Scholar
  14. [14]
    C. Schwarz, H. Regele, R. Steininger, C. Hansmann, G. Mayer and R. Oberbauer: “The contribution of adhesion molecule expression in donor kidney biopsies to early allograft dysfunction”, Transplantation, Vol. 71, (2001), pp. 1666–1670.PubMedCrossRefGoogle Scholar
  15. [15]
    A. Baradaran and H. Nasri: “Helicobacter pylori IgG antibodies in association with secondary hyperparathyroidism in end-stage renal failure patients undergoing regular hemodialysis”, Arch. Med. Sci., Vol. 1, (2005), pp. 148–151.Google Scholar
  16. [16]
    J. Rysz, R.A. Stolarek, E. Majewska, M. Banach, A. Cialkowska-Rysz and Z. Baj: “The increased levels of soluble TNFa receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis”, Am. J. Nephrol., Vol. 26, (2006), pp. 437–444.PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Jacek Rysz
    • 1
  • Eugeniusz Kocur
    • 1
  • Robert Błaszczak
    • 1
  • Robert Stolarek
    • 1
  1. 1.2nd Department of Family MedicineUniversity Hospital No. 2LodzPoland

Personalised recommendations